South Korean biotech Eyegene is advancing its recombinant botulinum toxin candidate EG-rBTX100, aiming to finish non-clinical studies in the second half of 2025 and enter human trials in 2027. The product, developed via E. coli expression rather than traditional Clostridium botulinum culture, could offer faster onset and longer duration. For overseas aesthetic distributors and clinic buyers, this signals a potential new supply option with a differentiated manufacturing process that avoids strain-origin controversies.
Development timeline and regulatory pathway
Eyegene plans to complete non-clinical studies for EG-rBTX100 in H2 2025 and submit an Investigational New Drug (IND) application by year-end, with human clinical trials starting in 2027. The company licensed global exclusive rights for the technology and aesthetic indications from Embrix in May 2024. Eyegene is collaborating with its largest shareholder, Korea BMI, to build an integrated model covering clinical development, regulatory approval, manufacturing, and sales.
Technology differentiation: recombinant production
Unlike conventional botulinum toxins that require culturing and purifying Clostridium botulinum bacteria, EG-rBTX100 is produced by expressing the toxin protein in E. coli using a gene-sequence-based recombinant method. This approach eliminates the structural burden of proving strain origin and history, which has been a compliance challenge for many Korean toxin manufacturers. The product is a 150kDa neurotoxin type, not the traditional 900kDa complex, and combines advantages from seven types and over 40 subtypes of botulinum toxins.
Expected efficacy profile and data validation
Eyegene anticipates that EG-rBTX100 will offer faster onset and extended duration compared to existing complex-type toxins. While the company has preliminary experimental data supporting these claims, formal non-clinical and clinical studies are required for validation. The current standard duration for botulinum toxin effects is three to four months; Eyegene aims to extend this period.
Overseas partnership and market strategy
Eyegene has received inquiries from one or two overseas companies since the technology in-license was announced and maintains contact with them. The company is prioritizing emerging markets, including China, over the US and Europe for its first overseas entry. China already has approved recombinant botulinum toxin products, suggesting a favorable regulatory environment for Eyegene's candidate.
What buyers should watch
Importers and distributors should monitor Eyegene's non-clinical data release in late 2025 and IND submission. The recombinant production method could offer a supply-chain advantage by reducing strain-related regulatory risks. The company's focus on faster onset and longer duration may appeal to clinics seeking differentiated injectable offerings. However, formal clinical data and regulatory approvals in target markets remain pending.
Source: Read the original report | Published: June 15, 2026